Claims for Patent: 7,354,574

Summary for Patent: 7,354,574

Title:	Treatment of ocular disease
Abstract:	A method and article to treat ocular disease with Cyclosporin A alone or with compounds related to Cyclosporin A for intraocular injection or implantation. Treatment does not result in ocular toxicity and encompasses age related macular degeneration, retinitis pigmentosa, and retinopathy such as diabetic retinopathy.
Inventor(s):	Peyman; Gholam A. (New Orleans, LA)
Assignee:	Advanced Ocular Systems Limited (Nedlands, AU)
Application Number:	10/289,772
Patent Claims:	1. A method of treating diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition consisting essentially of Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat diabetic retinopathy or retinitis pigmentosa without substantial toxicity to the patient. 2. The method of claim 1 comprising administering by retrobulbar, intravitreal, intraretinal, or subconjunctival injection. 3. The method of claim 1 wherein injection is subconjunctival at a dose in the range of about 1 ng/ml to about 500 .mu.g/ml, intravitreal at a dose in the range of about 1 .mu.g/0.1 ml to about 1000 .mu.g/0.1 ml, retrobulbar at a dose in the range of about 20 .mu.g/ml to about 1000 .mu.g/ml, or subretinal at a dose in the range of about 1 .mu.g/0.1 ml to about 100 .mu.g/0.1 ml. 4. The method of claim 1 wherein Cyclosporin A is injected at a dose in the range of about 20 .mu.g/ml to about 1000 .mu.g/ml. 5. A method of treating diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat diabetic retinopathy or retinitis pigmentosa without substantial toxicity to the patient. 6. The method of claim 5 comprising administering by retrobulbar, intravitreal, intraretinal, or subconjunctival injection. 7. The method of claim 5 wherein the composition further comprises an immunosuppressant selected from the group consisting of tacrolimus, cyclosphosphamide, sirolimus, atoposide, thiotepa, methotrexate, azathioprine, interferons, infliximab, etanercept, mycophenolate mofetil, 15-deoxyspergualin, thalidomide, glatiramer, leflunomide, vincristine, cytarabine, and combinations thereof. 8. The method of claim 1 wherein Cyclosporin A is provided in at least one of a microsphere, liposome, capsule or polymeric matrix. 9. The method of claim 5 wherein Cyclosporin A is provided in at least one of a microsphere, liposome, capsule or polymeric matrix. 10. A method of treating macular degeneration, diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat macular degeneration, diabetic retinopathy, or retinitis pigmentosa without substantial toxicity to the patient, wherein injection is subconjuctival at a dose in the range of about 1 .mu.g/ml to about 500 .mu.g/ml, intravitreal at a dose in the range of about 1 .mu.g/0.1 ml to about 1000 .mu.g/0.1 ml, retrobulbar at a dose in the range of about 20 .mu.g/ml to about 1000 .mu.g/ml, or subretinal at a dose in the range of about 1 .mu.g/0.1 ml to about 1000 .mu.g/0.1 ml. 11. A method of treating macular degeneration, diabetic retinopathy or retinitis pigmentosa in a patient in need thereof comprising intraocularly injecting a composition comprising Cyclosporin A in a pharmaceutically acceptable formulation and in an amount effective to treat macular degeneration, diabetic retinopathy, or retinitis pigmentosa without substantial toxicity to the patient, wherein Cyclosporin A is injected at a dose in the range of about 20 .mu.g/ml to about 1000 .mu.g/ml.

Details for Patent 7,354,574

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2039-02-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2039-02-26